

# REMARKS

Applicants have elected to amend the original claims solely for the purpose of prosecuting the amended claims in this application. These amended claims better encompass the full breadth of certain aspects of the present invention, notwithstanding applicants' belief that the original claims directed toward these aspects would have been allowable.

Favorable consideration and early allowance of all pending claims is requested.

# VERSION WITH MARKINGS TO SHOW CHANGES MADE

### CLAIM 38:

38. (once amended) A composition for inhibiting thrombotic conditions in blood comprising a compound of any one of Claims 8, 16, 24, 32, [and] or 37 and a pharmaceutically acceptable carrier.

## CLAIM 39:

39. (once amended) A composition for inhibiting thrombotic conditions in blood comprising a compound of any one of Claims 1 through 7, Claims 9 through 15, Claims 17 through 23, Claims 25 through 31, [and] or Claims 33 through 36 and a pharmaceutically acceptable carrier.

### CLAIM 40:

40. (once amended) A method for inhibiting thrombotic conditions in blood comprising adding to blood a therapeutically effective amount of a composition of any one of Claims [38 and 39] 1 through 37.

### CLAIM 41:

41. (once amended) A method for inhibiting formation of blood platelet aggregates in blood comprising adding to blood a therapeutically effective amount of a composition of any one of Claims [38 and 39] 1 through 37.

# CLAIM 42:

42. (once amended) A method for inhibiting thrombus formation in blood comprising adding to blood a therapeutically

effective amount of a composition of any one of Claims [38 and 39] 1 through 37.

#### CLAIM 43:

43. (once amended) A method for treating or preventing venuous thromboembolism and pulmonary embolism in a mammal comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims [38 and 39] 1 through 37.

# CLAIM 44:

44. (once amended) A method for treating or preventing deep vein thrombosis in a mammal comprising administering to the mammal a therapeutically effective amount of a composition of of any one of Claims [38 and 39] 1 through 37.

# CLAIM 45:

45. (once amended) A method for treating or preventing cardiogenic thromboembolism in a mammal comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims [38 and 39] 1 through 37.

## CLAIM 46:

46. (once amended) A method for treating or preventing thromboembolic stroke in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims [38 and 39] 1 through 37.

# CLAIM 47:

47. (once amended) A method for treating or preventing thrombosis associated with cancer and cancer chemotherapy in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims [38 and 39] 1 through 37.

# CLAIM 48:

48. (once amended) A method for treating or preventing unstable angina in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims [38 and 39] 1 through 37.

The Commissioner is hereby authorized to charge any deficiency or overpayment of the required fee to Deposit Account No. 19-1345.

Respectfully submitted,

Kathryn g Does

Kathryn J. Doty, Reg. No. 40,593 SENNIGER, POWERS, LEAVITT & ROEDEL One Metropolitan Square, 16th Floor

St. Louis, Missouri 63102

(314) 231-5400

Express Mail Label No. EL 739388090 US